Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.
暂无分享,去创建一个
[1] David C. Smith,et al. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium , 2011, Investigational New Drugs.
[2] B. Neyns,et al. Phase II study of sunitinib malate in patients with recurrent high-grade glioma , 2011, Journal of Neuro-Oncology.
[3] David A. Cheresh,et al. Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.
[4] Raymond Sawaya,et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] T. Mikkelsen,et al. Targeting integrins in malignant glioma , 2010, Targeted Oncology.
[6] Susan M. Chang,et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). , 2010, Neuro-oncology.
[7] F. Lieberman,et al. A prospective, randomized, open-label, phase III clinical trial of NovoTTF-100A versus best standard of care chemotherapy in patients with recurrent glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Thomas Benner,et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Alessia Pica,et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. McLendon,et al. Integrin alpha 6 regulates glioblastoma stem cells. , 2010, Cell stem cell.
[11] R. Stupp,et al. Bevacizumab and recurrent malignant gliomas: a European perspective. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Sosman,et al. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma , 2010, Cancer.
[13] M. Zaman,et al. The biomechanical integrin. , 2010, Journal of biomechanics.
[14] S. Piantadosi,et al. Current survival statistics for patients with newly diagnosed glioblastoma treated with radiation and temozolomide on research studies in the United States. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. Schwaiger,et al. Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. , 2009, Neuro-oncology.
[16] R. Stupp,et al. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. , 2009, Neuro-oncology.
[17] T. Mikkelsen,et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] T. Mikkelsen,et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] R. Stupp,et al. Will integrin inhibitors have proangiogenic effects in the clinic? , 2009, Nature Medicine.
[20] Stephen L. Brown,et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule‐dependency , 2009, International journal of cancer.
[21] J. Olson,et al. NABTT 0306: A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[23] C. Toulas,et al. Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma. , 2009, Cancer research.
[24] J. Norman,et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors , 2009, Nature Medicine.
[25] S. Hanks,et al. Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. , 2009, Cancer research.
[26] John A Butman,et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. Wicha,et al. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. , 2009, Cancer research.
[28] A. Tolcher,et al. Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study , 2008, Clinical Cancer Research.
[29] T. Mikkelsen,et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Visvader,et al. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. , 2008, Cancer research.
[31] J. Herman,et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] B. Garmy-Susini,et al. Integrins in angiogenesis and lymphangiogenesis , 2008, Nature Reviews Cancer.
[33] J. Tonn,et al. Expression of Integrin αvβ3 in Gliomas Correlates with Tumor Grade and Is not Restricted to Tumor Vasculature , 2008, Brain pathology.
[34] L. Tentori,et al. The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. , 2008, Oncology reports.
[35] Timothy F Cloughesy,et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. , 2008, Neuro-oncology.
[36] T. MacDonald,et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] John Sampson,et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] Daniel L. Gustafson,et al. Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors , 2007 .
[39] T. Mikkelsen,et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Robert A. Beckman,et al. Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.
[41] Darell D. Bigner,et al. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.
[42] Marie-Liesse Asselin-Labat,et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation , 2007, Nature Cell Biology.
[43] C. Bokemeyer,et al. Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. , 2006, Biochemical and biophysical research communications.
[44] A. Baron,et al. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[45] J. Buckner,et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. , 2007, Neuro-oncology.
[46] H. Friess,et al. A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer , 2006, BMC Cancer.
[47] X. Bu,et al. EFFECT OF THE ANGIOGENESIS INHIBITOR CILENGITIDE (EMD 121974) ON GLIOBLASTOMA GROWTH IN NUDE MICE , 2006, Neurosurgery.
[48] D. Hallahan,et al. Integrin αvβ3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non–small-cell lung cancer models , 2006 .
[49] M. Chellaiah,et al. Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells. , 2006, Experimental cell research.
[50] D. Bigner,et al. Recent advances in the treatment of malignant astrocytoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] D. Stupack,et al. A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. , 2006, The Journal of clinical investigation.
[52] David C. Smith,et al. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. , 2006, Clinical genitourinary cancer.
[53] R. Dubridge,et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. , 2006, Journal of experimental therapeutics & oncology.
[54] D. Hallahan,et al. Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. , 2006, International journal of radiation oncology, biology, physics.
[55] Jens Eickhoff,et al. Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion , 2005, Clinical Cancer Research.
[56] R. Hwang,et al. Integrin α4β1–VCAM-1–mediated adhesion between endothelial and mural cells is required for blood vessel maturation , 2005 .
[57] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[58] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[59] David J. Yang,et al. Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients , 2005, Clinical Cancer Research.
[60] C. Giachelli,et al. Src Kinase Activity Is Required for Integrin αVβ3-Mediated Activation of Nuclear Factor-κB* , 2005, Journal of Biological Chemistry.
[61] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[62] R. Hwang,et al. Integrin alpha4beta1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation. , 2005, The Journal of clinical investigation.
[63] C. Giachelli,et al. Src kinase activity is required for integrin alphaVbeta3-mediated activation of nuclear factor-kappaB. , 2005, The Journal of biological chemistry.
[64] S. Gerson. MGMT: its role in cancer aetiology and cancer therapeutics , 2004, Nature Reviews Cancer.
[65] G. Broggi,et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma , 2003, Journal of Neuro-Oncology.
[66] R. Henriksson,et al. Spatial Expression of VEGF-A in Human Glioma , 2002, Journal of Neuro-Oncology.
[67] Michael S. Pepper,et al. αvβ3 and αvβ5 integrin antagonists inhibit angiogenesis in vitro , 2004, Angiogenesis.
[68] A. Friedman,et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[69] Fang Tan,et al. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[70] J. Verweij,et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours , 2003 .
[71] S. Goodman,et al. alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. , 2003, Angiogenesis.
[72] J. Verweij,et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. , 2003, European journal of cancer.
[73] Kathleen R. Lamborn,et al. Cilengitide Targeting of αvβ3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts , 2002 .
[74] J. Tímár,et al. Multiple Roles for Platelet GPIIb/IIIa and αvβ3 Integrins in Tumor Growth, Angiogenesis, and Metastasis , 2002 .
[75] Robert C. Liddington,et al. Faculty Opinions recommendation of Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. , 2002 .
[76] K. Weinberg,et al. αv‐Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin , 2002, International journal of cancer.
[77] Thilo Stehle,et al. Crystal Structure of the Extracellular Segment of Integrin αVβ3 in Complex with an Arg-Gly-Asp Ligand , 2002, Science.
[78] Horst Kessler,et al. Nanomolar Small Molecule Inhibitors for αvβ6, αvβ5, and αvβ3 Integrins , 2002 .
[79] R. McLendon,et al. Dendritic Cells Pulsed with a Tumor-specific Peptide Induce Long-lasting Immunity and Are Effective against Murine Intracerebral Melanoma , 2002, Neurosurgery.
[80] S. Goodman,et al. Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins. , 2002, Journal of medicinal chemistry.
[81] J. Tímár,et al. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. , 2002, Cancer research.
[82] K. Lamborn,et al. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. , 2002, Cancer research.
[83] P. Black,et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. , 2001, Cancer research.
[84] P. Brenchley,et al. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas , 2001, Histopathology.
[85] F. Aoudjit,et al. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells , 2001, Oncogene.
[86] P. Black,et al. αvβ3 and αvβ5 Integrin Expression in Glioma Periphery , 2001 .
[87] F. Ross,et al. Superactivation of integrin alphavbeta3 by low antagonist concentrations. , 2001, Journal of cell science.
[88] Hiroyuki Shimada,et al. Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an &agr;v Integrin Antagonist , 2001, Neurosurgery.
[89] P. Black,et al. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. , 2001, Neurosurgery.
[90] F. Mitjans,et al. In vivo therapy of malignant melanoma by means of antagonists of αv integrins , 2000 .
[91] H. Friedman,et al. Temozolomide and treatment of malignant glioma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[92] F. Mitjans,et al. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. , 2000, International journal of cancer.
[93] C. Gladson. The extracellular matrix of gliomas: modulation of cell function. , 1999, Journal of Neuropathology and Experimental Neurology.
[94] M J Gleason,et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[95] Horst Kessler,et al. N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists , 1999 .
[96] S. Goodman,et al. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. , 1999, Journal of medicinal chemistry.
[97] K. Vuori,et al. The adaptor protein Crk connects multiple cellular stimuli to the JNK signaling pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[98] M. Berens,et al. Migration arrest in glioma cells is dependent on the αv integrin subunit , 1998 .
[99] C. Klein,et al. Invasive behaviour of human gliomas is mediated by interindividually different integrin patterns. , 1998, Anticancer research.
[100] N. Fausto,et al. NF-κB Mediates αvβ3 Integrin-induced Endothelial Cell Survival , 1998, The Journal of cell biology.
[101] M. Berens,et al. Migration arrest in glioma cells is dependent on the alphav integrin subunit. , 1998, Glia.
[102] K. Yamada,et al. Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors , 1996, The Journal of cell biology.
[103] R. Bjerkvig,et al. Stimulation of glioma‐cell migration by laminin and inhibition by anti‐α3 and anti‐β1 integrin antibodies , 1996 .
[104] S. Uccini,et al. Expression of adhesion molecules and extracellular matrix proteins in glioblastomas: relation to angiogenesis and spread , 1996, Histopathology.
[105] H. Hammes,et al. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor–type integrins inhibits retinal neovascularization , 1996, Nature Medicine.
[106] Jeffrey C. Allen,et al. Migration of Brain Tumor Cells on Extracellular Matrix Proteins in Vitro Correlates with Tumor Type and Grade and Involves αv and β1 Integrins , 1996 .
[107] D. Zagzag,et al. Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves alphaV and beta1 integrins. , 1996, Cancer research.
[108] R. Bjerkvig,et al. Stimulation of glioma-cell migration by laminin and inhibition by anti-alpha3 and anti-beta1 integrin antibodies. , 1996, International journal of cancer.
[109] David A. Cheresh,et al. Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.
[110] J. Wilcox,et al. Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. , 1995, Journal of cell science.
[111] Erkki Ruoslahti,et al. Phage Libraries Displaying Cyclic Peptides with Different Ring Sizes: Ligand Specificities of the RGD-Directed Integrins , 1995, Bio/Technology.
[112] D. Cheresh,et al. Definition of two angiogenic pathways by distinct alpha v integrins. , 1995, Science.
[113] A. Ullrich,et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.
[114] A. Ullrich,et al. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. , 1993, Cancer research.
[115] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.
[116] E. Keshet,et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.
[117] P. Humphrey,et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[118] D. Cheresh,et al. Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. , 1991, The Journal of clinical investigation.